Compare · AKAN vs DFTX
AKAN vs DFTX
Side-by-side comparison of Akanda Corp. (AKAN) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKAN and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.04B, about 492.7x AKAN ($8.2M).
- Over the past year, AKAN is down 78.4% and DFTX is up 167.7% - DFTX leads by 246.0 points.
- DFTX has been more active in the news (11 items in the past 4 weeks vs 1 for AKAN).
- DFTX has more recent analyst coverage (8 ratings vs 0 for AKAN).
PerformanceAKAN-78.37%DFTX+167.68%
2025-11-20+0.00%2026-11-20
- Company
- Akanda Corp.
- Definium Therapeutics Inc.
- Price
- -
- -
- Market cap
- $8.2M
- $4.04B
- 1M return
- +282.83%
- -19.04%
- 1Y return
- -78.37%
- +167.68%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 1
- 11
- Recent ratings
- 0
- 8
AKAN
Akanda Corp.
Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products in the United Kingdom, Lesotho, and internationally. It intends to supply cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.
Latest AKAN
- Amendment: SEC Form F-1/A filed by Akanda Corp.
- SEC Form RW filed by Akanda Corp.
- Amendment: SEC Form F-1/A filed by Akanda Corp.
- SEC Form F-1 filed by Akanda Corp.
- SEC Form 6-K filed by Akanda Corp.
- SEC Form 6-K filed by Akanda Corp.
- SEC Form 6-K filed by Akanda Corp.
- SEC Form 6-K filed by Akanda Corp.
- First Towers & Fiber Corp. Delivers First Cash Flow from New 200 KM Fiber Network, Eyes Expansion with Client
- SEC Form 6-K filed by Akanda Corp.
Latest DFTX
- SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.
- SEC Form 10-Q filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.
- Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
- Definium Therapeutics to Participate at Upcoming Investor Conferences
- Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026